109 related articles for article (PubMed ID: 33847849)
1. Evaluation of Encequidar as An Intestinal P-gp and BCRP Specific Inhibitor to Assess the Role of Intestinal P-gp and BCRP in Drug-Drug Interactions.
Chu J; Panfen E; Wang L; Marino A; Chen XQ; Fancher RM; Landage R; Patil O; Desai SD; Shah D; Xue Y; Sinz M; Shen H
Pharm Res; 2023 Nov; 40(11):2567-2584. PubMed ID: 37523014
[TBL] [Abstract][Full Text] [Related]
2. Assessment of contribution of BCRP to intestinal absorption of various drugs using portal-systemic blood concentration difference model in mice.
Kawahara I; Nishikawa S; Yamamoto A; Kono Y; Fujita T
Pharmacol Res Perspect; 2020 Feb; 8(1):e00544. PubMed ID: 31988753
[TBL] [Abstract][Full Text] [Related]
3. Physiologically based absorption modeling to predict the bioequivalence of two apixaban formulations.
Luo T; Wang L; Ruan Z; Lou H; Yang D; Wang Z; Zhao P; Jiang B
Clin Transl Sci; 2024 May; 17(5):e13819. PubMed ID: 38747478
[TBL] [Abstract][Full Text] [Related]
4. Development of immediate-release formulation with reliable absorption of rivaroxaban in various meal regimes.
Bosák J; Šíma M; Krejčí T; Obadalová I; Šmardová J; Kozlík P; Křížek T; Beránek J; Hauser T; Slanař O
Clin Transl Sci; 2024 May; 17(5):e13820. PubMed ID: 38738493
[TBL] [Abstract][Full Text] [Related]
5. Dietary gallic acid as an antioxidant: A review of its food industry applications, health benefits, bioavailability, nano-delivery systems, and drug interactions.
Xiang Z; Guan H; Zhao X; Xie Q; Xie Z; Cai F; Dang R; Li M; Wang C
Food Res Int; 2024 Mar; 180():114068. PubMed ID: 38395544
[TBL] [Abstract][Full Text] [Related]
6. Meta-Analysis of Food Effect on Oral Absorption of Efflux Transporter Substrate Drugs: Does Delayed Gastric Emptying Influence Drug Transport Kinetics?
Sharma S; Prasad B
Pharmaceutics; 2021 Jul; 13(7):. PubMed ID: 34371727
[TBL] [Abstract][Full Text] [Related]
7. Pharmacogenetics of Bleeding and Thromboembolic Events in Direct Oral Anticoagulant Users.
Lähteenmäki J; Vuorinen AL; Pajula J; Harno K; Lehto M; Niemi M; van Gils M
Clin Pharmacol Ther; 2021 Sep; 110(3):768-776. PubMed ID: 34043814
[TBL] [Abstract][Full Text] [Related]
8. Antiplatelet therapy with or without anticoagulant therapy for lower extremity peripheral artery disease: A systematic review.
Rahmatian D; Barry AR
Am J Health Syst Pharm; 2021 Nov; 78(23):2132-2141. PubMed ID: 34059879
[TBL] [Abstract][Full Text] [Related]
9. A retrospective analysis of bleeding risk with rivaroxaban, enoxaparin, and aspirin following total joint arthroplasty or revision.
Watts PJ; Kopstein M; Harkness W; Cornett B; Dziadkowiec O; Hicks ME; Hassan S; Scherbak D
Pharmacotherapy; 2021 Jul; 41(7):608-615. PubMed ID: 34050956
[TBL] [Abstract][Full Text] [Related]
10. Non-Vitamin K Antagonist Oral Anticoagulants for the Treatment of Cerebral Venous Sinus Thrombosis: a Retrospective, Matched Cohort Analysis.
Giles JA; Balasetti VKS; Zazulia AR
Neurocrit Care; 2021 Dec; 35(3):783-788. PubMed ID: 34046861
[TBL] [Abstract][Full Text] [Related]
11. Thromboprophylaxis with rivaroxaban in patients with malignancy and central venous lines (TRIM-Line): A two-center open-label pilot randomized controlled trial.
Ikesaka R; Siegal D; Mallick R; Wang TF; Witham D; Webb C; Carrier M;
Res Pract Thromb Haemost; 2021 May; 5(4):e12517. PubMed ID: 34027291
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and Safety of Direct Oral Anticoagulants in Venous Thromboembolism Compared to Traditional Anticoagulants in Morbidly Obese Patients: A Systematic Review and Meta-Analysis.
Katel A; Aryal M; Neupane A; Gosain R; Pathak R; Bhandari Y; Kouides P
Cureus; 2021 Apr; 13(4):e14572. PubMed ID: 34026385
[TBL] [Abstract][Full Text] [Related]
13. Risk of Severe Abnormal Uterine Bleeding Associated with Rivaroxaban Compared with Apixaban, Dabigatran and Warfarin.
Eworuke E; Hou L; Zhang R; Wong HL; Waldron P; Anderson A; Gassman A; Moeny D; Huang TY
Drug Saf; 2021 Jul; 44(7):753-763. PubMed ID: 34014506
[TBL] [Abstract][Full Text] [Related]
14. Physiologically-based pharmacokinetic modeling to predict drug-drug interaction of enzalutamide with combined P-gp and CYP3A substrates.
Otsuka Y; Poondru S; Bonate PL; Rose RH; Jamei M; Ushigome F; Minematsu T
J Pharmacokinet Pharmacodyn; 2023 Oct; 50(5):365-376. PubMed ID: 37344637
[TBL] [Abstract][Full Text] [Related]
15. Impact of the Genotype and Phenotype of CYP3A and P-gp on the Apixaban and Rivaroxaban Exposure in a Real-World Setting.
Lenoir C; Terrier J; Gloor Y; Gosselin P; Daali Y; Combescure C; Desmeules JA; Samer CF; Reny JL; Rollason V
J Pers Med; 2022 Mar; 12(4):. PubMed ID: 35455642
[TBL] [Abstract][Full Text] [Related]
16. Analyzing Potential Intestinal Transporter Drug-Drug Interactions: Reevaluating Ticagrelor Interaction Studies.
Liu S; Sodhi JK; Benet LZ
Pharm Res; 2021 Oct; 38(10):1639-1644. PubMed ID: 34729703
[TBL] [Abstract][Full Text] [Related]
17. Investigating Intestinal Transporter Involvement in Rivaroxaban Disposition through Examination of Changes in Absorption.
Kou W; Sodhi JK; Wu X; Benet LZ
Pharm Res; 2021 May; 38(5):795-801. PubMed ID: 33847849
[TBL] [Abstract][Full Text] [Related]
18. Intestinal Efflux Transporters P-gp and BCRP Are Not Clinically Relevant in Apixaban Disposition.
Sodhi JK; Liu S; Benet LZ
Pharm Res; 2020 Sep; 37(10):208. PubMed ID: 32996065
[TBL] [Abstract][Full Text] [Related]
19. Physiologically-Based Pharmacokinetic Modeling for the Prediction of a Drug-Drug Interaction of Combined Effects on P-glycoprotein and Cytochrome P450 3A.
Otsuka Y; Choules MP; Bonate PL; Komatsu K
CPT Pharmacometrics Syst Pharmacol; 2020 Nov; 9(11):659-669. PubMed ID: 33030266
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
